Join to view full profile
Beth Israel Hospital330 Brookline AvenueBoston, MA 02215
Phone+1 617-667-7081
Fax+1 617-975-5665
Dr. Tung is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1987
Harvard Medical SchoolClass of 1984
Certifications & Licensure
MA State Medical License 1990 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2017
- CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012-2017
- CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012-2017
Clinical Trials
- Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Roles: Contact, Principal Investigator
- ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16
Publications & Presentations
PubMed
- Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy.Nadine M Tung, Tianyu Li, Judy E Garber
Journal of Clinical Oncology. 2026-07-07 - 5 citationsMenopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.Joanne Kotsopoulos, Marta Seca, Jacek Gronwald, Tomasz Huzarski, Pål Møller
Journal of the National Cancer Institute. 2026-05-01 - Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant inor.Adriana I Apostol, Jacek Gronwald, Cezary Cybulski, Raymond H Kim, Pål Møller
Journal of Clinical Oncology. 2026-04-01
Press Mentions
Pre-Operative THP Leads to pCR in 64% of Early-Stage HER2+ ER- Breast Cancer PatientsJune 2nd, 2025- Pre-Operative THP Achieves Pathological Complete Response in Two-Thirds of Early-Stage HER2-Positive, ER-Negative Breast Cancer PatientsJune 2nd, 2025
- REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast CancerMay 14th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
